BR0013281A - Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais - Google Patents

Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais

Info

Publication number
BR0013281A
BR0013281A BR0013281-0A BR0013281A BR0013281A BR 0013281 A BR0013281 A BR 0013281A BR 0013281 A BR0013281 A BR 0013281A BR 0013281 A BR0013281 A BR 0013281A
Authority
BR
Brazil
Prior art keywords
preparation
arylmethyl
carbonylamino
thiazole derivatives
antitumor agents
Prior art date
Application number
BR0013281-0A
Other languages
English (en)
Inventor
Paolo Pevarello
Raffaella Amici
Mario Varasi
Manuela Villa
Anna Vulpetti
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0013281A publication Critical patent/BR0013281A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"DERIVADOS DE ARILMETIL-CARBONILAMINO-TIAZOL, PROCESSO PARA SUA PREPARAçãO E SEU USO COMO AGENTES ANTITUMORAIS". Derivados de 2-amino-1,3-tiazol representados pela fórmula ( I ) ou ( II ): onde R, R~ 1~, R~ 2~ e R~ 3~ estão definidos no relatório descritivo, ou sais farmaceuticamente aceitáveis dos mesmos, são úteis em, por exemplo, tratamento de câncer, desordens celulares proliferativas, mal de Alzheimer, infecções virais, doenças auto-imunes ou doenças neurodegenerativas.
BR0013281-0A 1999-08-12 2000-08-11 Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais BR0013281A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/372,832 US6114365A (en) 1999-08-12 1999-08-12 Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
PCT/IB2000/001423 WO2001014353A1 (en) 1999-08-12 2000-08-11 Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents

Publications (1)

Publication Number Publication Date
BR0013281A true BR0013281A (pt) 2002-06-18

Family

ID=23469806

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0013281-0A BR0013281A (pt) 1999-08-12 2000-08-11 Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais

Country Status (36)

Country Link
US (3) US6114365A (pt)
EP (1) EP1204649B1 (pt)
JP (1) JP4864260B2 (pt)
KR (2) KR100773709B1 (pt)
CN (1) CN100410245C (pt)
AP (1) AP1853A (pt)
AT (1) ATE375987T1 (pt)
AU (1) AU782882B2 (pt)
BG (1) BG65484B1 (pt)
BR (1) BR0013281A (pt)
CA (1) CA2381097C (pt)
CY (1) CY1107108T1 (pt)
CZ (1) CZ303138B6 (pt)
DE (1) DE60036803T2 (pt)
DK (1) DK1204649T3 (pt)
EA (1) EA005375B1 (pt)
EE (1) EE04939B1 (pt)
ES (1) ES2295056T3 (pt)
GE (1) GEP20053475B (pt)
HK (1) HK1054233B (pt)
HR (1) HRP20020127B1 (pt)
HU (1) HUP0202492A3 (pt)
IL (2) IL147924A0 (pt)
IS (1) IS2594B (pt)
MA (1) MA25433A1 (pt)
MX (1) MXPA02001508A (pt)
NO (1) NO323576B1 (pt)
NZ (1) NZ517236A (pt)
OA (1) OA12047A (pt)
PT (1) PT1204649E (pt)
RS (1) RS50300B (pt)
SI (1) SI1204649T1 (pt)
SK (1) SK287373B6 (pt)
UA (1) UA72538C2 (pt)
WO (1) WO2001014353A1 (pt)
ZA (1) ZA200201117B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020150921A1 (en) * 1996-02-09 2002-10-17 Francis Barany Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
AU779089B2 (en) 1999-04-15 2005-01-06 Bristol-Myers Squibb Holdings Ireland Unlimited Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6291504B1 (en) 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20040048844A1 (en) * 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
JP2004517840A (ja) * 2000-11-27 2004-06-17 フアルマシア・イタリア・エツセ・ピー・アー フェニルアセトアミド−ピラゾール誘導体およびそれの抗腫瘍薬としての使用
US6706718B2 (en) * 2000-12-01 2004-03-16 Bristol-Myers Squibb Company 3-(2,4-dimethylthiazol-5-yl)indeno[1,2-c]pyrazol-4-one derivatives and their uses
JP2004538247A (ja) 2000-12-08 2004-12-24 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー セミカルバジド及びサイクリン依存キナーゼ阻害剤
JP4405726B2 (ja) * 2000-12-21 2010-01-27 ブリストル−マイヤーズ スクイブ カンパニー Tecファミリーチロシンキナーゼのチアゾリルインヒビター
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
ATE345341T1 (de) * 2001-07-19 2006-12-15 Pfizer Italia Srl Phenylacetamido-thiazole verbindungen, verfahren zu ihren herstellung und ihre anwendung als antitumor mittel
EP1724270A3 (en) 2001-07-19 2007-01-03 Pfizer Italia S.r.l. Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
DE60233420D1 (de) * 2001-09-27 2009-10-01 Equispharm Co Ltd Fumagillolderivate und verfahren zu deren herstellung
AU2002351748B2 (en) * 2001-12-21 2009-07-09 Novo Nordisk A/S Amide derivatives as GK activators
WO2004002481A1 (en) * 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
CA2515728A1 (en) * 2003-02-12 2004-08-26 Pfizer Inc. Antiproliferative 2-(sulfo-phenyl)-aminothiazole derivatives
BRPI0407618A (pt) * 2003-02-21 2006-02-21 Pfizer derivados de tiazole amino substituidos com cicloalquilo contendo n e composições farmacêuticas para inibição da proliferação celular e métodos para a sua utilização
JP4758337B2 (ja) * 2003-03-31 2011-08-24 株式会社アールテック・ウエノ 血管透過性亢進疾患を治療する方法
WO2005014591A1 (en) * 2003-07-15 2005-02-17 L'oreal 2-acylamino or 2-sulfonylamino-1, 3-thiazoles as couplers for the oxidation dyeing of keratin fibres
FR2857664B1 (fr) * 2003-07-15 2007-12-14 Oreal Nouveaux derives thiazoles et utilisation de ces derives pour la teinture des fibres keratiniques
US7351727B2 (en) * 2003-09-02 2008-04-01 Bristol-Myers Squibb Company Inhibitors of 15-lipoxygenase
US20050074424A1 (en) * 2003-10-03 2005-04-07 Lev Salnikov Using polyion polymers with glucose infusion for a cancer selective chemotherapy compound and method
WO2005060956A1 (en) * 2003-12-12 2005-07-07 University Of Maryland, Baltimore IMMUNOMODULATORY COMPOUNDS THAT TARGET AND INHIBIT THE pY+3 BINDING SITE OF TYROSENE KINASE p56 LCK SH2 DOMAIN
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
EP2298292A3 (en) 2004-06-18 2011-08-10 Agennix USA Inc. Kinase inhibitors for treating cancers
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7410988B2 (en) * 2004-08-13 2008-08-12 Genentech, Inc. 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
US8541457B2 (en) * 2005-06-03 2013-09-24 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors
JP2009500378A (ja) * 2005-07-08 2009-01-08 ノボ・ノルデイスク・エー/エス グルコキナーゼ活性化剤としてのジシクロアルキルカルバモイル尿素
US7884210B2 (en) * 2005-07-14 2011-02-08 Novo Nordisk A/S Ureido-thiazole glucokinase activators
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JP2010515701A (ja) * 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー/エス ウレアグルコキナーゼアクチベーター
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー/エス ウレアグルコキナーゼアクチベーター
NZ578944A (en) * 2007-02-13 2011-03-31 Ab Science PROCESS FOR THE SYNTHESIS OF 2-AMINOTHIAZOLE COMPOUNDS SUCH AS 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide AS KINASE INHIBITORS
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity
TWI437986B (zh) * 2008-01-31 2014-05-21 R Tech Ueno Ltd 噻唑衍生物及使用該衍生物作為vap-1抑制劑之用途
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
AU2009313927A1 (en) 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
TWI504598B (zh) * 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
DE102009043260A1 (de) * 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
HU0900798D0 (en) 2009-12-21 2010-03-01 Vichem Chemie Kutato Kft 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
US8883793B2 (en) 2010-12-29 2014-11-11 Development Center For Biotechnology Tubulin inhibitors and methods of using the same
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
CN103387551B (zh) * 2012-05-11 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 噻唑类化合物及其用途
ES2661717T3 (es) 2012-08-23 2018-04-03 Virostatics Srl Derivados de aminopirimidina 4,6-disustituidos novedosos
SG11201808402RA (en) 2016-04-11 2018-10-30 Genfit Methods of treatment for cholestatic and fibrotic diseases
EP3720436A4 (en) 2017-12-06 2021-06-02 Lin Bioscience, Pty Ltd. TUBULIN INHIBITORS
AU2019215799B2 (en) * 2018-02-01 2022-04-14 The University Of Sydney Anti-cancer compounds
MX2020008905A (es) 2018-06-12 2020-12-03 Vtv Therapeutics Llc Usos terapeuticos de activadores de glucoquinasa en combinacion con insulina o analogos de insulinas.
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
EP3941900A1 (en) 2019-03-22 2022-01-26 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
WO2021162054A1 (ja) * 2020-02-10 2021-08-19 学校法人順天堂 2型リアノジン受容体活性抑制剤
CN115322208B (zh) * 2021-05-10 2023-04-11 中国药科大学 2-氨基噻唑类衍生物及其制备方法和医药用途
WO2023182780A1 (ko) * 2022-03-22 2023-09-28 오토텔릭바이오 주식회사 티아졸 유도체 화합물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1252204B (de) * 1960-04-20 1967-10-19 Ortho Pharmaceutical Corporation, Raritan, N. J. (V. St. A.) Verfahren zur Herstellung von 2,4-Dinitropyrrolderivaten
TW513418B (en) * 1996-07-31 2002-12-11 Otsuka Pharma Co Ltd Thiazole derivatives, their production and use
JPH1095777A (ja) * 1996-07-31 1998-04-14 Otsuka Pharmaceut Co Ltd チアゾール誘導体
US6794392B1 (en) * 1996-09-30 2004-09-21 Schering Aktiengesellschaft Cell differentiation inducer
BR9815200A (pt) * 1997-10-27 2001-10-16 Agouron Pharma Composto, composição farmacêutica e método de tratamento de uma doença ou distúrbio mediado pela inibição de cdk4 ou um complexo de cdk4/ciclina
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ATE288904T1 (de) * 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
AU779089B2 (en) * 1999-04-15 2005-01-06 Bristol-Myers Squibb Holdings Ireland Unlimited Company Cyclic protein tyrosine kinase inhibitors
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
US6992081B2 (en) * 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
SE0102440D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compound
DE60221627D1 (de) * 2001-12-21 2007-09-20 Virochem Pharma Inc Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors

Also Published As

Publication number Publication date
PL353588A1 (en) 2003-12-01
ATE375987T1 (de) 2007-11-15
OA12047A (en) 2006-05-02
AU782882B2 (en) 2005-09-08
HK1054233B (zh) 2009-05-29
HK1054233A1 (en) 2003-11-21
KR20070074003A (ko) 2007-07-10
EE200200064A (et) 2003-04-15
MXPA02001508A (es) 2003-07-21
EP1204649A1 (en) 2002-05-15
IS2594B (is) 2010-03-15
NZ517236A (en) 2004-11-26
EE04939B1 (et) 2007-12-17
RS50300B (sr) 2009-09-08
JP2003507461A (ja) 2003-02-25
NO20020683D0 (no) 2002-02-11
US6784198B1 (en) 2004-08-31
US20050004120A1 (en) 2005-01-06
WO2001014353A1 (en) 2001-03-01
CZ303138B6 (cs) 2012-04-25
IL147924A (en) 2008-03-20
CN1425009A (zh) 2003-06-18
KR100827563B1 (ko) 2008-05-07
EA200200247A1 (ru) 2002-08-29
CZ2002486A3 (cs) 2002-11-13
DE60036803T2 (de) 2008-07-24
CN100410245C (zh) 2008-08-13
BG106481A (en) 2002-09-30
ES2295056T3 (es) 2008-04-16
ZA200201117B (en) 2003-04-30
US6114365A (en) 2000-09-05
AU7440000A (en) 2001-03-19
MA25433A1 (fr) 2002-04-01
HUP0202492A3 (en) 2004-12-28
DE60036803D1 (de) 2007-11-29
IL147924A0 (en) 2002-08-14
BG65484B1 (bg) 2008-09-30
KR20020060159A (ko) 2002-07-16
HRP20020127B1 (en) 2010-08-31
SI1204649T1 (sl) 2008-02-29
SK1802002A3 (en) 2003-05-02
JP4864260B2 (ja) 2012-02-01
EA005375B1 (ru) 2005-02-24
NO323576B1 (no) 2007-06-11
CA2381097C (en) 2009-06-16
AP1853A (en) 2008-05-29
EP1204649B1 (en) 2007-10-17
HRP20020127A2 (en) 2003-04-30
CY1107108T1 (el) 2012-10-24
YU9702A (sh) 2004-11-25
PT1204649E (pt) 2008-01-10
GEP20053475B (en) 2005-03-25
NO20020683L (no) 2002-04-10
UA72538C2 (en) 2005-03-15
SK287373B6 (sk) 2010-08-09
HUP0202492A2 (hu) 2002-11-28
IS6264A (is) 2002-02-11
DK1204649T3 (da) 2007-12-03
CA2381097A1 (en) 2001-03-01
KR100773709B1 (ko) 2007-11-09
AP2002002441A0 (en) 2002-03-31

Similar Documents

Publication Publication Date Title
BR0013281A (pt) Derivados de arilmetil-carbonilamino-tiazol, processo para sua preparação e seu uso como agentes antitumorais
BR0013277A (pt) Derivados de 3(5) ureido-pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
BR0013143A (pt) Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais
GB0102687D0 (en) Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
AU2003218989A1 (en) Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
NO20040547L (no) Amino-ftalazinonderivater aktive som kinaseinhibitorer, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende disse.
BR0212841A (pt) Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
MXPA02012164A (es) Derivados de tiofeno activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden.
MXPA04000920A (es) Derivados de aminoisoxazol activos como inhibidores de la cinasa.
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
BRPI0418179A (pt) derivados de pirrolo[2,3-b] piridina ativos como inibidores de quinase, processo para sua preparação e composições farmacêuticas os compreendendo
ME00017B (me) Derivati kamptotecina koji imaju antitumorno dejstvo
BRPI0418184A (pt) derivados de pirrol[2,3-b]piridina ativos como inibidores de quinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR0315988A (pt) Derivados de diidropirimido[4,5-d]pirimidinona substituìda por amino, sua produção e uso como agentes farmacêuticos
BRPI0414330A (pt) composto, processo para preparação do mesmo, métodos para produção de um efeito antibacteriano, para inibição de dna girase bacteriana, e para tratamento de uma infecção bacteriana em um animal de sangue quente, uso de um composto, e, composição farmacêutica
EA199901031A1 (ru) Производные бензимидазола
DE602004014163D1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
BRPI0408486A (pt) derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
NO20021337L (no) 4-benzylaminokinolinkonjugater med gallesyre og deres heteroanaloger, fremgangsmåte for deres fremstilling, legemidlerinneholdende disse forbindelser og deres anvendelse

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.